Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.77 |
| ▸ | CNR2 | P34972 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | IAPP | P10997 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2938428 | 0.92 | CNR1 (0.71) | CNR1CNR2IGF1RALOX15KAT8 | |
| SCHEMBL28653265 | 0.89 | CNR1 (0.61) | CNR1CNR2NPC1MAPK1RAB9A | |
| SCHEMBL662610 | 0.87 | CNR1 (1.00) | CNR1CNR2HPGDNPSR1ALOX5 | |
| SCHEMBL29380189 | 0.87 | CNR1 (1.00) | CNR1CNR2HPGDNPSR1ALOX5 | |
| SCHEMBL8940800 | 0.87 | GABRA1 (0.60) | CNR1CNR2MAPK1ALOX5LMNA | |
| Magnolol SCHEMBL5511922 | 0.87 | GABRA1 (0.72) | CNR1CNR2NPC1MAPK1RAB9A | |
| SCHEMBL4591101 | 0.86 | BACE1 (0.66) | CNR1CNR2NPC1MAPK1RAB9A | |
| SCHEMBL9818748 | 0.86 | ALOX5 (0.58) | CNR1CNR2NPC1MAPK1RAB9A | |
| SCHEMBL7083434 | 0.86 | CNR1 (0.58) | CNR1CNR2NPC1MAPK1RAB9A | |
| SCHEMBL20429859 | 0.85 | CNR1 (0.57) | CNR1CNR2NPC1MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539022-B1 | ORAL CARE COMPOSITIONS COMPRISING MAGNOLIA BARK EXTRACT OR A SYNTHETIC ANALOG THEREOF | COLGATE PALMOLIVE CO (US) | 2018-08-01 | — | — | EP | claimed |
| CN-104053663-B | Process for purifying organodiphosphite compounds | 巴斯夫欧洲公司 | 2017-07-04 | — | — | CN | claimed |
| EP-2539022-A2 | ORAL CARE COMPOSITIONS COMPRISING MAGNOLIA BARK EXTRACT OR A SYNTHETIC ANALOG THEREOF | Colgate-Palmolive Company (US) | 2013-01-02 | — | — | EP | claimed |
| US-20120308489-A1 | ORAL CARE COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2012-12-06 | — | — | US | claimed |
| US-20120294812-A1 | ORAL CARE COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2012-11-22 | — | — | US | claimed |
| EP-2523676-A1 | ORAL CARE COMPOSITIONS | Colgate-Palmolive Company (US) | 2012-11-21 | — | — | EP | claimed |
| WO-2011106493-A2 | ORAL CARE COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2011-09-01 | — | — | WO | claimed |
| WO-2011106492-A1 | ORAL CARE COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2011-09-01 | — | — | WO | claimed |
| EP-2539022-B1 | ORAL CARE COMPOSITIONS COMPRISING MAGNOLIA BARK EXTRACT OR A SYNTHETIC ANALOG THEREOF | COLGATE PALMOLIVE CO (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2539022-B1 | ORAL CARE COMPOSITIONS COMPRISING MAGNOLIA BARK EXTRACT OR A SYNTHETIC ANALOG THEREOF | COLGATE PALMOLIVE CO (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9801940-B2 | Oral care compositions | COLGATE-PALMOLIVE COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-9801940-B2 | Oral care compositions | COLGATE-PALMOLIVE COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-9801940-B2 | Oral care compositions | COLGATE-PALMOLIVE COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| EP-2790650-B1 | SOLUBILIZED MAGNOLOL ANALOGS | COLGATE PALMOLIVE CO (US) | 2017-05-24 | — | — | EP | disclosed |
| WO-2011075136-A1 | CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS | COLGATE-PALMOLIVE COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-2266666-A1 | Oral compositions containing biphenol antibacterial compounds | Colgate-Palmolive Company (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266666-A1 | Oral compositions containing biphenol antibacterial compounds | Colgate-Palmolive Company (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1830925-A1 | ORAL COMPOSITIONS CONTAINING BIPHENOL ANTIBACTERIAL COMPOUNDS | Colgate-Palmolive Company (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006071654-A1 | ORAL COMPOSITIONS CONTAINING BIPHENOL ANTIBACTERIAL COMPOUNDS | COLGATE-PALMOLIVE COMPANY (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20060140880-A1 | Oral compositions containing biphenol antibacterial compounds | COLGATE-PALMOLIVE | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120294812-A1 | ORAL CARE COMPOSITIONS | MLEC, TAS2R40, FHIT | CNR1 4307/4885CNR2 4300/4885NPC1 195/4885 |
| US-20120308489-A1 | ORAL CARE COMPOSITIONS | MLEC, TAS2R40, FHIT | CNR1 4307/4885CNR2 4300/4885NPC1 195/4885 |
| US-20060140880-A1 | Oral compositions containing biphenol antibacterial compounds | BPGM, ABCB11, UGT1A10 | CNR1 3087/4885CNR2 3431/4885NPC1 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.